Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$30.91 USD
-0.14 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $30.90 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Denali Therapeutics Inc. (DNLI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$39.00 | $90.00 | $22.00 | 25.60% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Denali Therapeutics Inc. comes to $39.00. The forecasts range from a low of $22.00 to a high of $90.00. The average price target represents an increase of 25.6% from the last closing price of $31.05.
Analyst Price Targets (15)
Broker Rating
Denali Therapeutics Inc. currently has an average brokerage recommendation (ABR) of 1.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on 16 recommendations.
Of the 16 recommendations deriving the current ABR, 15 are Strong Buy, representing 93.75% of all recommendations. A month ago, Strong Buy represented 93.75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 15 | 15 | 15 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.13 | 1.13 | 1.13 | 1.13 | 1.13 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/9/2024 | Cantor Fitzgerald & Co | Josh Schimmer | Strong Buy | Strong Buy |
9/4/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
9/3/2024 | Not Identified | Not Identified | Hold | Hold |
8/15/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/31/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | B. Riley Securities | Mayank Mamtani | Strong Buy | Strong Buy |
5/8/2024 | SVB Securities | Marc Goodman | Strong Buy | Strong Buy |
4/9/2024 | UBS | Research Department | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Brendan Smith | Strong Buy | Strong Buy |
2/29/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
2/27/2024 | BTIG | Thomas Shrader | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.13 |
ABR (Last week) | 1.13 |
# of Recs in ABR | 16 |
Average Target Price | $39.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 79 of 253 |
Current Quarter EPS Est: | -0.61 |
DNLI FAQs
Denali Therapeutics Inc. (DNLI) currently has an average brokerage recommendation (ABR) of 1.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 16 brokerage firms.
The average price target for Denali Therapeutics Inc. (DNLI) is $39.00. The current on short-term price targets is based on 13 reports.
The forecasts for Denali Therapeutics Inc. (DNLI) range from a low of $22 to a high of $90. The average price target represents a increase of $26.17 from the last closing price of $30.91.
The current UPSIDE for Denali Therapeutics Inc. (DNLI) is 26.17%
Based on short-term price targets offered by 15 analysts, the average price target for Denali Therapeutics Inc. comes to $39.00. The forecasts range from a low of $22.00 to a high of $90.00. The average price target represents an increase of 25.6% from the last closing price of $31.05.